Hansoh Pharmaceutical Group's (HKG:3692) HS-20093 for injection obtained China's National Medical Products Administration's (NMPA) approval to be added as a breakthrough-therapy-designated drug for the treatment of patients with osteosarcoma, a type of bone cancer, a Tuesday bourse filing said.
The Chinese regulator approved the drug for the treatment of patients who have progressed on at least two prior lines of therapy.
HS-20093, also known as GSK5764227, is a B7-H3-targeted antibody-drug conjugate that is being developed in multiple clinical studies of small-cell lung cancer, head and neck cancers, and other solid tumors.
The injection has also been granted breakthrough therapy designation by NMPA previously for lung cancer and from the US Food and Drug Administration for the treatment of relapsed or refractory extensive-stage small-cell lung cancer, ES-SCLC.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.